Healthcare Services company Vimta Labs announced Q1FY26 results Total Income for Q1FY26 was at Rs 993 million. EBITDA for Q1FY26 was Rs 354 million; EBITDA margin was at 35.7%. PBT for Q1FY26 was at Rs 253 million. Q1FY26 PAT was at Rs 189 million; PAT margin was at 19.0% Basic EPS in Q1FY26 was Rs 4.2 Harita Vasireddi, Managing Director, Vimta Labs , said: “We are happy to report a revenue of Rs 993 million for the quarter which was driven by pharmaceutical & food contract research and testing services that we provide. I am pleased with the consistent progress Vimta continues to make in strengthening its service portfolio and deepening customer relationships across sectors. Vimta completes a successful USFDA GCP inspection with zero Form 483 observations and received letter of cGMP compliance from ANSM (EMA) during the quarter. These outcomes are a reflection of Vimta's strong commitment to quality, and scientific rigor. As a part of our efforts to enhance shareholder value, the Board has approved a Bonus issue in the ratio of 1:1, showcasing the company's strong financial position, confidence in future growth, and commitment to rewarding its shareholders. Our focus remains on expanding our market reach and capabilities, fostering innovation, and creating sustainable long-term value for all our stakeholders.” Result PDF